학술논문
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study
Document Type
Article
Author
van den Bent, M.J.; Tesileanu, C.M.S.; Taal, W.; de Heer, I.; French, P.; Dubbink, H.J.; Kros, J.M.; Wick, W.; Sanson, M.; Brandes, A.A.; Clement, P.M.; Erridge, S.; Vogelbaum, M.A.; Nowak, A.K.; Baurain, J.F.; Mason, W.P.; Wheeler, H.; Chinot, O.L.; Gill, S.; Griffin, M.; Rogers, L.; Rudà, R.; Weller, M.; McBain, C.; Reijneveld, J.; Enting, R.H.; Caparrotti, F.; Lesimple, T.; Clenton, S.; Gijtenbeek, A.; Lim, E.; Herrlinger, U.; Hau, P.; Dhermain, F.; Aldape, K.; Jenkins, R.B.; Wesseling, P.; Nuyens, S.; Golfinopoulos, V.; Gorlia, T.; Baumert, B.G.
Source
In: The Lancet Oncology . (The Lancet Oncology, June 2021, 22(6):813-823)
Subject
Language
English
ISSN
14745488
14702045
14702045